Home

TFF Pharmaceuticals Announces Additional Positive Data from the Tacrolimus Inhalation Powder (TFF TAC) Phase...

TW's Take: TFF-TAC continues to have the data to support potential blockbuster status. Once the balance sheet issues are resolved, the value here will...

Golden Years?

One recurring theme I've stressed in this newsletter is concern around the Federal deficit, a looming disaster that seemingly is ignored by most politicians....

enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial Officer

TW's Take: this is a solid hire as his experience dovetails nicely into getting the VenoValve acquired by a larger device company post approval. Appointment...

INmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator...

TW's Take: outstanding data sets the stage for potential partnering of INB03. Novel Immunotherapy Approach Targets Soluble Tumor Necrosis Factor to Overcome Resistance and...

Ciao from Sicily! Or, beheaded in Palermo…

Greetings from Sicily, a land of great beauty, great food and great wine. It's a lovely time of year to visit here, neither too...

Movano Health Closes $24 Million Private Placement

TW's Take: Great news for MOVE as they needed cash and this is a nice endorsement by insiders and a quality strategic. Financing included...

Premium Subscriber Easter Sunday Update…

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

TFF Pharmaceuticals Announces Oral Presentation of Interim Data from the Phase 2 Study of...

TW's Take: further endorsement of the value of TAC. I believe partners will be highly interested in this program going forward as the data...

The Bull Market Trudges On…When Will It End?

Markets had another strong week as the bull market continues apace. I continue to be constructive on micro-caps as the relative disparity remains far...

TFF Pharmaceuticals Announces $1.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

TW's Take: the balance sheet continues to be the biggest risk to TFFP. Once that's squared away, the stock should perform quite well. FORT WORTH,...

TFFP Premium Subscriber Trading Update…

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

TFF Pharmaceuticals Announces Update on Clinical Programs

TW's Take: very positive announcement in many ways. The data for both drugs is excellent with TAC surpassing even the highest expectations. If VORI...

QUEST RESOURCE HOLDING CORPORATION REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIAL RESULTS

TW's Take: organic growth finally taking off. Well positioned for a big 2024. New Business Wins, Client Renewals, Revenue Growth, and Pipeline Growth Reflect...

Running in Place…It’s All About Execution

You ever have that dream where you're being chased and your feet just won't move? You're stuck in the ground and, no matter what...

Brief Update for Premium Subscribers…

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award...

TW's Take: Quite an honor for Mark. His “goal of creating a scalable cancer immunotherapy that can be easily delivered to a large number...

Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress

TW's Take: Anixa's cancer vaccine continues to demonstrate excellent immune responses and is hopefully partnered off sometime in the next year at a significant...

Spring Is Here…Micro-caps Are Emerging From Their Slumber

Last weekend we were in Seattle visiting the kids. It was wet and cold, a very typical Seattle winter weekend, kinda similar to what...

enVVeno Announces VenoValve Top Line Results…

~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial...

TW's Take: outstanding data makes reimbursement and approval highly likely with significant post-approval uptake. I believe this sets the stage for an acquisition within...

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.